Several other equities analysts also recently weighed in on OBSV. HC Wainwright downgraded ObsEva from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 30th. Canaccord Genuity Group lowered ObsEva from a “buy” rating to a “hold” rating and cut their price objective for the company from $12.00 to $1.00 in a research report on Monday, August 1st. Finally, Cantor Fitzgerald lowered ObsEva from an “overweight” rating to a “neutral” rating in a research report on Thursday, July 28th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.40.
ObsEva Stock Performance
Shares of OBSV stock opened at $0.18 on Friday. The company has a market cap of $13.75 million, a price-to-earnings ratio of -0.23 and a beta of 0.46. The stock has a 50 day simple moving average of $0.17 and a 200-day simple moving average of $0.80. ObsEva has a 12-month low of $0.13 and a 12-month high of $2.45. The company has a current ratio of 2.98, a quick ratio of 2.98 and a debt-to-equity ratio of 1.18.
Institutional Trading of ObsEva
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
- Get a free copy of the StockNews.com research report on ObsEva (OBSV)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.